- Home
- ARWR
as 01-17-2025 4:00pm EST
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 2.4B | IPO Year: | 1993 |
| Target Price: | $43.33 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.05 - $36.72 | Next Earning Date: | 02-04-2025 |
| Revenue: | $3,551,000 | Revenue Growth: | -98.52% |
| Revenue Growth (this year): | 3402.96% | Revenue Growth (next year): | 123.96% |
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hamilton James C | ARWR | Chief Discovery/Trans Medicine | Jan 4 '25 | Sell | $19.90 | 32,729 | $648,824.25 | 272,122 | |
| Myszkowski Kenneth Allen | ARWR | Chief Financial Officer | Jan 4 '25 | Sell | $19.79 | 45,167 | $893,095.40 | 482,835 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Jan 2 '25 | Sell | $19.05 | 11,520 | $219,456.00 | 3,764,252 | |
| OLUKOTUN ADEOYE Y | ARWR | Director | Dec 27 '24 | Sell | $20.00 | 2,850 | $57,000.00 | 36,740 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 23 '24 | Sell | $19.59 | 12,563 | $246,109.17 | 3,764,252 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 18 '24 | Sell | $21.46 | 26,712 | $567,485.84 | 3,764,252 | |
| Waddill William D. | ARWR | Director | Dec 16 '24 | Sell | $21.97 | 7,495 | $164,665.08 | 44,125 | |
| GIVEN DOUGLAS B | ARWR | Director | Dec 16 '24 | Sell | $21.97 | 5,547 | $121,555.88 | 124,167 | |
| Vakiener Victoria | ARWR | Director | Dec 16 '24 | Sell | $21.91 | 8,994 | $197,058.54 | 21,211 |
Latest Arrowhead Pharmaceuticals Inc. News
ARWR Breaking Stock News: Dive into ARWR Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Arrowhead Pharmaceuticals' New Drug Application for Plozasiran Accepted by FDA
Business Wire
a day ago
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Argus Research
4 days ago
ARWR: Lowering target price to $19.00
Clinical Trials Arena
a month ago
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial
Argus Research
a month ago
ARWR: Lowering target price to $16.00
MT Newswires
a month ago
Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug
Business Wire
a month ago
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
MT Newswires
a month ago
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,486, According to a Recent SEC Filing
Compare ARWR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.